Long acting adrenocorticotropic hormone - Cerium Pharmaceuticals
Alternative Names: SNP-ACTH (1-39) GelLatest Information Update: 13 Jun 2023
At a glance
- Originator Cerium Pharmaceuticals
- Class Melanocortins; Peptides
- Mechanism of Action Melanocortin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Membranous glomerulonephritis
Most Recent Events
- 13 Mar 2023 Phase-III clinical trials in Membranous glomerulonephritis in USA (SC) (NCT05696613)
- 08 Feb 2023 Phase-I/II clinical trials in Membranous glomerulonephritis in USA (SC) (Cerium Pharmaceuticals pipeline, January 2023)
- 31 Jan 2023 Cerium Pharmaceuticals plans a phase III trial for Membranous glomerulonephritis (SC, Injection) in February 2023 (NCT05696613)